Results 171 to 180 of about 97,116 (340)

Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells

Small Methods, EarlyView.
Cardenolide‐functionalized extracellular vesicles enable targeted delivery of the chemotherapeutic doxorubicin to A549 lung cancer cells by binding Na+/K+‐ATPase, which is overexpressed in these cells. Surface‐modified, drug‐loaded EVs exhibit enhanced cytotoxicity compared to unmodified EVs and free drug, suggesting this system may lower the effective
Maja Dorfner, Anika Mifka, Rodrigo Maia de Pádua, Izabella Thaís da Silva, Iara Zanella Guterres, Lorenzo Sana, Gregor Fuhrmann, Jennifer Munkert   +7 more
wiley   +1 more source

Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation

, 2023
Ayşe Tarbın Jannuzzi, Nalan Sümeyra Korkmaz, Ayşenur Günaydın Akyıldız, Sema Arslan Eseryel, Betül Karademir, Büket Alpertunga   +5 more
openalex   +2 more sources

Preclinical Toxicity Screening of Sodium Dodecanoyloxybenzenesulfonate (LOBS) as a New Alternative Biocide Using In Vitro and In Vivo Models

Environmental Toxicology, EarlyView.
ABSTRACT Sodium hypochlorite is a well‐established biocide extensively used in both living and industrial environments; however, exposure to it or improper handling can harm the human body and the environment. Thus, safer alternatives to sodium hypochlorite are required.
Seung Eui Min, Seunghee Oh, Min Seong Jang, Kang‐Hyun Han   +3 more
wiley   +1 more source

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

cardiotoxic

Citation: 'cardiotoxic' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.15535 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

PS-091 Dispersion Of The Qt And Qtc Intervals-early Marker Of Anthracycline Induced Cardiotoxicity In Children With Malignant Hemopathies [PDF]

, 2014
L. Dimitriu, AG Dimitriu, Ingrith Miron, C.G. Mandric   +3 more
openalex   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure [PDF]

, 2023
Forat Lutfi, Briha Ansari, Afraah Hawa, Al‐Ola Abdallah, Zubair Shah, Andre Khazak, Hussam Hawamdeh, Marc Hoffmann, Muhammad Umair Mushtaq, William Wesson, Aliya Rashid, Maggie Nelson, Leyla Shune, Sunil Abhyankar, Joseph P. McGuirk, Charles Porter, Nausheen Ahmed   +16 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source